After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Reata Pharmaceuticals Inc. (RETA) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.26, or 0.74%, to $35.50. The Reata Pharmaceuticals Inc. has recorded 14,993 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Reata Pharmaceuticals Announces Participation in the Guggenheim 2022 Immunology and Neurology Conference and the Stifel 2022 Healthcare Conference.
RETA belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $35.24 and fluctuated between $36.86 as its day high and $33.85 as its day low. The current market capitalization of Reata Pharmaceuticals Inc. is $1.27B. A total of 0.6 million shares were traded on the day, compared to an average of 709.94K shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, RETA has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 10 BUYs and 0 SELLs from insiders. Insiders purchased 26,278 shares during that period but sold 0.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for RETA in the last 3 months, the mean price target is $62.40 with high estimates of $115.00 and low estimates of $35.00. In terms of 52-week highs and lows, RETA has a high of $43.90 and a low of $18.47.
As of this writing, RETA has an earnings estimate of -$2.18 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$2.05 per share and a lower estimate of -$2.63. The company reported an EPS of -$2.03 in the last quarter, which was 6.50% higher than expectations of -$2.17.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 10 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for RETA is Hold with a score of 4.60. A total of 7 analysts rated the stock as Buy while 1 rated it as Overweight while 2 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.